Drug Trial Radar · NCT04958265
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
41
Actual
Start
Nov 17, 2021
Primary completion
Jul 4, 2025
Study completion May 19, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Jul 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 28 days, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
Conditions
- Atypical Hemolytic Uremic Syndrome
Interventions
CrovalimabDrug
Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing =\> 40 to \<100 kg) or 1500 mg IV (for participants weighing \>=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing =\> 40 to \<100 kg) or 1020 mg SC (for participants weighing \>=100 kg). Enrollment of participants weighing \<40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing \>=20 kg to \<40 kg, followed by Group 2 participants weighing \>=5 kg to \<20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Naïve Cohort: Percentage of Participants With Complete Thrombotic Microangiopathy Response (cTMAr) Anytime From Baseline to Week 25 (After 24 Weeks on Treatment)Time frame: From baseline up to Week 25
Locations
20 sites in 10 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
University of Nebraska
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
UZ Gent
Ghent, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Inst. Da Criança- Faculdade de Medicina Usp
São Paulo, São Paulo, Brazil
CHU Sainte-Justine
Montreal, Quebec, Canada
Peking University First Hospital
Beijing, China
Beijing Children's Hospital, Capital Medical University
Beijing, China
The children's hospital , Zhejiang university school of medicine
Hangzhou, China
Hôpital Arnaud de Villeneuve
Montpellier, France
Gh Necker Enfants Malades
Paris, France
Institute of Kidney Diseases and Research Centre
Ahmedabad, Gujarat, India
Medanta-The Medicity
Gurgaon, Haryana, India
All India Institute Of Medical Sciences (AIIMS)
New Delhi, National Capital Territory of Delhi, India
Aichi Children?s Health and Medical Center
Aichi, Japan
Chiba Children's Hospital
Chibashi, Chibaken, Japan
Hospital de Especialidades Puerta de Hierro S.A de C.V.
Zapopan, Mexico
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Instytut ?Centrum Zdrowia Matki Polki
Lodz, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.